CG Oncology (NASDAQ:CGON) Shares Down 3.9%

CG Oncology, Inc. (NASDAQ:CGONGet Free Report) shares fell 3.9% during trading on Friday . The stock traded as low as $29.27 and last traded at $29.75. 254,417 shares changed hands during trading, a decline of 62% from the average session volume of 673,075 shares. The stock had previously closed at $30.97.

Wall Street Analyst Weigh In

Several brokerages have recently commented on CGON. Morgan Stanley began coverage on CG Oncology in a report on Tuesday, February 20th. They set an “overweight” rating and a $55.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $75.00 price objective on shares of CG Oncology in a report on Monday, May 6th. Cantor Fitzgerald restated an “overweight” rating and issued a $75.00 target price on shares of CG Oncology in a research note on Thursday, May 2nd. Finally, The Goldman Sachs Group upgraded CG Oncology from a “neutral” rating to a “buy” rating and raised their target price for the stock from $43.00 to $50.00 in a research note on Monday, May 13th.

Check Out Our Latest Stock Report on CGON

CG Oncology Stock Down 3.2 %

The firm’s 50 day moving average price is $37.11.

Institutional Investors Weigh In On CG Oncology

A number of institutional investors have recently modified their holdings of the business. Ameritas Investment Partners Inc. acquired a new stake in shares of CG Oncology during the 1st quarter valued at about $102,000. California State Teachers Retirement System acquired a new stake in shares of CG Oncology during the 1st quarter valued at about $103,000. BNP Paribas Financial Markets acquired a new stake in shares of CG Oncology during the 1st quarter valued at about $492,000. Capstone Investment Advisors LLC acquired a new stake in shares of CG Oncology during the 1st quarter valued at about $806,000. Finally, Blackstone Inc. acquired a new stake in shares of CG Oncology during the 1st quarter valued at about $1,098,000. 26.56% of the stock is currently owned by institutional investors and hedge funds.

CG Oncology Company Profile

(Get Free Report)

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.

Featured Stories

Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.